Director, Real-World Biostatistics – Oncology Focus

EPM Scientific; Philadelphia (Philadelphia County); Sur place; USD 230 000 - 270 000; Plein temps

Résumé du poste

A reputable pharmaceutical organization seeks a Director of Real World Biostatistics to lead statistical analyses and methodologies across drug development. This pivotal role emphasizes mentoring junior biostatisticians, overseeing complex real-world studies, and ensuring compliance with regulatory standards. Candidates should hold a Ph.D. in a relevant field with considerable experience in pharmaceutical settings and be adept at using programming languages such as R and Python. Competitive compensation package includes a base salary of $230-270,000 plus bonuses and equity.

Qualifications

• Ph.D. required with 8+ years of industry experience.
• Strong experience in drug development using RWD.
• Expertise in leading health outcomes research.

Responsabilités

• Lead end-to-end execution of real-world studies.
• Mentor junior biostatisticians and oversee projects.
• Present analyses at scientific conferences.

Connaissances

Pharmaceutical data analysis

Real-world evidence expertise

Advanced biostatistical techniques

Statistical programming (R, Python)

Project leadership

Communication of statistical concepts

Formation

Ph.D. in Biostatistics, Statistics, Epidemiology, or a related quantitative field

Master's degree with 10+ years of experience

Outils

R

Python

Description du poste

A reputable pharmaceutical organization seeks a Director of Real World Biostatistics to lead statistical analyses and methodologies across drug development. This pivotal role emphasizes mentoring junior biostatisticians, overseeing complex real-world studies, and ensuring compliance with regulatory standards. Candidates should hold a Ph.D. in a relevant field with considerable experience in pharmaceutical settings and be adept at using programming languages such as R and Python. Competitive compensation package includes a base salary of $230-270,000 plus bonuses and equity.